Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795]
This appeal hearing will hear appeals against the Final Appraisal Document for the above technology by the following organisations:
- Incyte Corporation
- Lymphoma Action
- NCRI-ACP-RCP
The appeal panel will convene on Monday 14 November 2022 at 10.00am via Zoom to hear oral representations from the appellants.
This page was last updated: